Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2005-09-21
2008-10-21
Huynh, Phuong (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S133100, C424S143100, C530S387100, C530S387300, C530S388100, C530S388220
Reexamination Certificate
active
07438906
ABSTRACT:
Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
REFERENCES:
patent: 4629783 (1986-12-01), Cosand
patent: 4714759 (1987-12-01), Whitaker
patent: 4816567 (1989-03-01), Cabilly
patent: 4940782 (1990-07-01), Rup
patent: 4975369 (1990-12-01), Beavers
patent: 5348876 (1994-09-01), Michaelson
patent: 5428133 (1995-06-01), Chang
patent: 5543144 (1996-08-01), Chang
patent: 5585089 (1996-12-01), Queen
patent: 5635600 (1997-06-01), Fanger
patent: 5648260 (1997-07-01), Winter
patent: 5648267 (1997-07-01), Reff
patent: 5658570 (1997-08-01), Newman
patent: 5681722 (1997-10-01), Newman
patent: 5736137 (1998-04-01), Anderson
patent: 5811524 (1998-09-01), Brams
patent: 6001358 (1999-12-01), Black
patent: 6011138 (2000-01-01), Reff
patent: 6136310 (2000-10-01), Hanna
patent: 6383487 (2002-05-01), Amlot
patent: 6521230 (2003-02-01), Amlot
patent: 6893636 (2005-05-01), Reff
patent: 7033589 (2006-04-01), Reff et al.
patent: 7223392 (2007-05-01), Reff
patent: WO 87/07302 (1987-12-01), None
patent: WO 88/06891 (1988-09-01), None
patent: WO 89/10138 (1989-11-01), None
patent: WO 92/17207 (1992-10-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 96/12741 (1996-05-01), None
patent: WO 96/12742 (1996-05-01), None
Clejan et al, J Cell Mol. Med. 9(2): 457-461, 2005.
Ballow et al, J Allergy Clin Immunol 118: 1209-15, 2006.
Webster's II New Riverside University Dictionary, p. 944, 1984.
Capron et al., “Heterogeneous expression of CD23 epitopes by eosinophils from patients. Relationships with IgE-meidated functions,”Eur. J. Immunol., 1991, 21: 2423-2429.
Caruthers (1987) “DNA Synthesis as an Aid to Protein Modification and Design,” in Oxender & Fox (eds),Protein Engineering, Alan R. Liss, Inc., New York, pp. 68-69.
Griffin et al., “Immunologic abnormalities accompanying acute and chronic viral infections,”Rev. Infect. Dis., 1991, 13 Suppl 1: S129-133. (abstract only).
Jones et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature, 1986, 321: 522-525.
Koutsonikolis et al., “Asymptomatic lymphoma associated with elevation of immunoglobulin E,”Ann. Allergy, Asthma,&Immunol., 1997, 78: 27-28.
Norderhaug et al., “Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells,”J. Immunol. Methods, 1997 204(1): 77-87. (abstract only).
Paul et al.,Fundamental Immunology, 3rdEdition, 1993, p. 826.
Abaza et al., “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization: demonstration with region 94-100 (antigenic site 3) of myoglobin,”J. Protein Chem., 1992, 11(5):433-444.
Abedi et al., “Immunoglobulin production in severe combined immunodeficient (SCID) mice reconstituted with human peripheral blood mononuclear cells”,Eur. J. Immunol., 1992, 22:823-828.
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody”,Mol Immunol, 1993, 30:105-108.
Aubry et al., “CD21 is a ligand for CD23 and regulates IgE production”,Nature, 1992, 358:505-507.
Beers et al. (eds),The Merck Manual of Diagnosis and Therapy, 17thEdition, 1999, Whitehouse Station, New Jersey, pp. 416-422.
Berkow (ed),The Merck Manual, 16thEdition, 1992, Rahway, New Jersey, pp. 1305-1312, 1334-1338.
Bettler et al., “Binding site for IgE of the human lymphocyte low-affinity Fc epsilon receptor (Fc epsilon RII/CD23) is confined to the domain homologous with animal lectins”,Proc. Natl. Acad. Sci. USA, 1989, 86:7118-7122.
Bheeka Escura et al., “Regulation and targeting of T-cell immune responses by IgE and IgG antibodies,”Immunol., 1995, 86(3):343-350.
Boerner et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes”,J. Immunol., 1991, 147:86.
Bonnefoy et al., “A new role for CD23 in inflammation”,Immunol. Today, 1996, 17:418-420.
Bonnefoy et al., “Inhibition of human interleukin 4-induced IgE synthesis by a subset of anti-CD23/Fc epsilon RII monoclonal antibodies”,Eur. J. Immunol., 1990, 20:139-144.
Bonnefoy et al., “Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD23 is a low affinity receptor for IgE,”J. Immunol., 1987, 138(9):2970-2978.
Bonnefoy et al., “Receptors for IgE”,Curr. Opin Immunol., 1993, 5:944-949.
Bonnefoy et al., “Regulation of IgE synthesis by CD23/CD21 interaction”,Int. Arch. Allergy Immunol., 1995, 107:40-42.
Bosma et al., “A severe combined immunodeficiency mutation in the mouse”,Nature, 1983, 301:527-530.
Boulet et al. , “Inhibitory Effects of an Anti-Ige Antibody E25 on Allergen-induced Early Asthmatic Response,”Am. J. Respir. Crit. Care Med., 1997, 155:1835-1844.
Bourget et al., “CD20 monoclonal antibodies decrease interleukin-4-stimulated expression of the low-affinity receptor for IgE (Fc epsilon RII/CD23) in human B cells by increasing the extent of its cleavage,”Eur. J. Immunol., 1995, 12(7):1872-1876.
Burton et al., “Human antibody effector function,” in Dixon (ed),Advances in Immunology, 1992, Academic Press Inc., vol. 51, pp. 1-84.
Busse et al.,J. Allergy Clin. Immunol., 2001, 107(2):abstract No. 354.
Capon et al., “Designing CD4 immunoadhesins for AIDS therapy,”Nature, 1989, 337:525-531.
Carballido et al., “IL-4 induces human B cell maturation and IgE synthesis in SCID-hu mice. Inhibition of ongoing IgE production by in vivo treatment with an IL-4/IL-13 receptor antagonist,”J. Immunol., 1995, 155:4162-4170.
Carroll et al., “Mouse x human heterohybridomas as fusion partners with human B cell tumors”, Nussenzweig et al. (eds),Journal of Immunological Methods, 1986, Elsevier Science Publishers B.V., vol. 89, pp. 61-72.
Casale et al., “Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis,”J. Allergy Clin. Immunol., 1997, 100:110-120.
Chen et al., “Enzyme immunoassay for prostate-specific antigen and its diagnostic application in prostate cancer,”J. Formos. Med. Assoc., 1992, 91:1039-1043. (abstract only).
Chiang et al., “Direct cDNA cloning of the rearranged immunoglobulin variable region,”Biotechniques, 1989, 7(4):360-366.
Co et al., “Chimeric and humanized antibodies with specificity for the CD33 antigen”,J . Immunol., 1992, 148(3):1149-1154.
Co et al., “Humanized anti-Lewis Y antibodies: in vitro properties and pharmacokinetics in rhesus monkeys”,Cancer Res., 1996, 56:1118-1125.
Cotran et al. (ed),Robbins Pathologic Basis of Disease, 5thed., 1994, W.B. Saunders Co., pp. 197-199.
Coyle et al., “Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody,”J. Exp. Med., 1996, 183:1303-1310.
Cruse et al.,Illustrated Dictionary of Immunology, 1995, CRC Press, p. 69.
D'Ambrosio et al., “Recruitment and activation of PTP1C in negative regulation of antigen receptor signaling by Fc gamma RIIB1,”Science, 1995, 268:293-297 (1995).
de Vries, “Novel fundamental approaches to intervening in IgE-mediated allergic diseases,”J. Invest. Dermatol., 1994, 102:141-144. (abstract only).
Delespesse et al., “Human IgE-binding factors”,Immunol. Today, 1989, 10:159-164.
Durum et al., “Proinflammatory Cytokines and Immunity,” in Paul et al. (eds.),Fundamental Immunology, 3rd Edition, 1993, Raven Press Ltd., pp. 801-835.
Fahy et al., “The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allerg
Kloetzer William S.
Nakamura Takehiko
Reff Mitchell E.
Biogen Idec MA Inc.
Huynh Phuong
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4004069